Shapiro Capital Management LLC lifted its stake in Catalent Inc (NASDAQ:CTLT) by 0.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,667,160 shares of the company’s stock after purchasing an additional 12,500 shares during the period. Shapiro Capital Management LLC owned about 1.33% of Catalent worth $58,517,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Massachusetts Financial Services Co. MA grew its holdings in Catalent by 1.2% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 10,909 shares of the company’s stock worth $309,000 after acquiring an additional 130 shares in the last quarter. Aperio Group LLC grew its holdings in Catalent by 0.8% during the 2nd quarter. Aperio Group LLC now owns 23,088 shares of the company’s stock worth $810,000 after acquiring an additional 190 shares in the last quarter. Capstone Asset Management Co. grew its holdings in Catalent by 2.3% during the 2nd quarter. Capstone Asset Management Co. now owns 10,130 shares of the company’s stock worth $356,000 after acquiring an additional 230 shares in the last quarter. Advantus Capital Management Inc grew its holdings in Catalent by 3.0% during the 1st quarter. Advantus Capital Management Inc now owns 15,972 shares of the company’s stock worth $452,000 after acquiring an additional 468 shares in the last quarter. Finally, Commerce Bank grew its holdings in Catalent by 3.3% during the 2nd quarter. Commerce Bank now owns 17,315 shares of the company’s stock worth $608,000 after acquiring an additional 555 shares in the last quarter.
Several research analysts have issued reports on the stock. Needham & Company LLC assumed coverage on shares of Catalent in a report on Tuesday, September 12th. They set a “hold” rating and a $42.00 target price on the stock. BidaskClub cut shares of Catalent from a “buy” rating to a “hold” rating in a report on Friday. Piper Jaffray Companies reiterated a “buy” rating and set a $45.00 target price on shares of Catalent in a report on Tuesday, August 29th. Bank of America Corporation reiterated a “buy” rating and set a $40.00 target price (up from $38.00) on shares of Catalent in a report on Tuesday, August 29th. Finally, Zacks Investment Research cut shares of Catalent from a “buy” rating to a “hold” rating in a report on Friday, August 18th. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Catalent presently has an average rating of “Buy” and a consensus price target of $36.80.
In other news, SVP Christine Dolan sold 1,594 shares of the business’s stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $38.75, for a total transaction of $61,767.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Catalent Inc (NASDAQ CTLT) traded down 3.13% during mid-day trading on Tuesday, hitting $38.65. 472,962 shares of the company’s stock traded hands. Catalent Inc has a one year low of $21.83 and a one year high of $42.22. The stock has a market cap of $4.84 billion and a PE ratio of 44.43. The firm’s 50-day moving average price is $37.07 and its 200-day moving average price is $33.66.
Catalent (NASDAQ:CTLT) last announced its quarterly earnings data on Monday, August 28th. The company reported $0.65 EPS for the quarter, topping the Zacks’ consensus estimate of $0.57 by $0.08. Catalent had a return on equity of 36.29% and a net margin of 10.02%. The business had revenue of $616.90 million during the quarter, compared to the consensus estimate of $547.48 million. During the same period in the previous year, the company posted $0.52 earnings per share. The business’s revenue for the quarter was up 15.9% on a year-over-year basis. On average, analysts forecast that Catalent Inc will post $1.61 EPS for the current fiscal year.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NASDAQ:CTLT).
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.